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Background: Current methods for testing treatments for veterinary surgical site infections can successfully emulate
elements of a chronic wound, but these are time consuming and costly, requiring specialized laboratory equipment
and considerable space to house study animals. Microfluidic devices however, can be coated with collagen and
maintained at basal body temperature, providing a more cost-effective and space-saving model of a chronic wound.
Our study assesses the applicability of a new microfluidic model by testing the activity of DispersinB against biofilms of
methicillin-resistant Staphylococcus pseudintermedius (MRSP); DispersinB has been shown to prevent biofilm growth of
Staphylococcus epidermidis, another prominent wound colonizer.
Results: We successfully developed a microfluidic model to examine the effects of antimicrobial therapy on biofilms
formed by organisms associated with wound infections in companion animals (e.g. MRSP). Although, we were unable
to recapitulate previous findings that DispersinB-Gentamycin is highly effective against Staphylococcal biofilms using
this model, we were able to confirm its effect in a microtitre plate. Differences in the experimental conditions likely
account for this result (e.g. strains tested, flow conditions, treatment time, etc.). In the microtitre plate assay, DispersinB
inhibited biofilm growth after a 24 hour period; there was an inverse relationship between the concentration of
DispersinB-Gentamycin and the amount of biofilm remaining following treatment. Collagen-coated microtitre plates
showed a similar result, but this did not correlate as well; collagen, the most abundant protein in the body may help to
retain the biomass of treated biofilms.
Conclusions: Our model may be useful in examining the effect of treatment on wound infections, although we
acknowledge that in this model the test organisms may be more recalcitrant to antimicrobials than in other published
systems. We contend that this may in fact better represent the conditions in vivo, where organisms associated with
chronic wound infections are highly resistant to antimicrobials.
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Methicillin-resistant Staphylococcus pseudintermedius
(MRSP) bacterial biofilms have rapidly emerged as a
serious complication in surgical site and wound infec-
tions in companion animals [1]. MRSP infections are
being reported with increasing frequency in veterinary
hospitals and have become the leading cause of pyo-
derma and surgical site infections in dogs [1,2]. MRSP
infections are of tremendous concern in companion* Correspondence: sneethir@uoguelph.ca
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article, unless otherwise stated.animals because they are challenging to eradicate, as they
are typically recalcitrant to traditional antimicrobial ther-
apy [1-3]. Therefore, it is imperative that the foundations
of antimicrobial resistance be better understood.
Antimicrobial treatments may be tested in chronic ani-
mal wound infections on living animals, but this can
lead to undesired consequences if the treatment were to
have adverse effects, which may actually worsen infec-
tion or the presentation of the wound [1-4]. One way to
avoid in vivo studies in veterinary hospitals would be to
simulate a wound using synthetic material where pos-
sible [5]. Ideally, such models would display all the char-
acteristics of an animal wound without having to use theCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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conducted that look at this possibility [6-8], but they pri-
marily use materials to simulate the environment with-
out necessarily simulating the wound itself. Finding a
method that increases the accuracy of replicating wound
tissue, which at the same time is inexpensive and saves
both space and materials, would be most desirable. Such
a model could emulate a true wound environment, while
remaining easily deployable and could be repeated a suf-
ficient number of times to facilitate advanced statistical
analysis and model prediction.
Microfluidic technology is a relatively new field that
can be applied to studying, evaluating, and under-
standing primary biofilm growth characteristics, ideally
as a means to improve antimicrobial therapies that tar-
get pathogenic biofilms [9]. Microfluidic-based wound
models can overcome the drawbacks associated with
animal studies in testing antimicrobial agents, such as
variability and lack of reproducibility. Microfluidics’
well-controlled reaction conditions, accurate delivery
of drugs, and lower dead volumes will enable the devel-
opment of novel skin models for testing antimicrobial
agents against biofilms in a wound setting. Studies
have shown that copious amounts of biofilm will read-
ily form in channels of microscopic size [10], which
can allow researchers to study biofilm growth in a
confined, controllable, and reproducible space. For
example, models with small channel volumes and high
surface areas can be used to mimic the spatial environ-
ment of a blood vessel [11]. Microfluidic technology can
be applied to more precisely understand the evolution
of antimicrobial resistance in biofilms by creating dy-
namic concentration gradients, such as those found at
sites where biofilms form [12,13]. Microfluidics can also
be used to study the spatial and temporal growth of mi-
croorganisms, as well as motility and chemotaxis [12,13].
In this study we investigated the efficacy of an antimicro-
bial agent against MRSP biofilms in a wound model we
developed using microfluidic platforms.
DispersinB, a glycoside hydrolase enzyme, has been
shown to successfully inhibit biofilm growth in Staphylo-
coccus species, specifically S. epidermidis [14-16]. This
suggests that DispersinB may be an effective candidate
for testing the viability of new wound infection models;
these results can then be verified using established mi-
crotitre plate assay methods [15,17]. The efficacy of
DispersinB has been investigated using conventional
techniques for studying wound-associated bacteria, such
as Klebsiella penumoniae and Staphylococcus epider-
midis [18]. However, its effect on MRSP, another key
wound infection-causing bacterium, has not been in-
vestigated. At wound sites, a range of multidrug re-
sistant pathogens can be encountered, resulting in
tremendous morbidity, mortality, and healthcare costsfor both animals and humans. Biofilm formation has
been hypothesized as the reason for the emergence of
highly resistant and pathogenic MRSP clones [19].
Therefore, we examined the antimicrobial resistance
profiles of MRSP biofilms by evaluating the efficacy of
DispersinB in combination with Gentamycin in our newly
developed model. Collagen coated polymeric microfluidic
platforms, coupled with microscopy, enabled the in situ
observation of antimicrobial susceptibility and the evo-
lution of distinct microbial morphologies over the course
of biofilm formation. Our results helped to determine an
effective minimal concentration of DispersinB and Gen-
tamycin that may be sufficient to eradicate MRSP biofilms.
Ultimately, this microfluidic assay may be used to improve
the clinical management of wound associated biofilm in-
fections in companion animals.Materials and methods
Bacterial strains and antimicrobial agent
The study bacteria chosen for use in this investigation
were selected based on data from a previous study of
clarithromycin efficacy against MRSP biofilms [1]. The
three strains chosen were selected to demonstrate effi-
cacy of DispersinB with gentamicin against bacteria of
varying adherence capabilities. High, medium, and low
adherence capability were represented by the A12, A92,
and SP102 isolates, respectively. The mixture of Disper-
sinB and gentamicin used was 1 mg/mL gentamicin and
200 μg/mL DispersinB, which was suspended in 50 mM
sodium phosphate (pH 5.8) and 100 mM NaCl (Kane
Biotech Inc., Winnipeg, Canada).Culture and dye methods
Each strain was sub-cultured from frozen stock onto
Columbia agar plates with 5% sheep blood and grown
for 24 hours at 35°C. For microfluidic tests, test tubes
containing 5 ml tryptic soy broth with 1% glucose (TSB-G)
were inoculated with A92 isolates to the equivalent tur-
bidity of a 0.5 McFarland standard, then incubated for 3
hours at 35°C and diluted with 5 ml of sterile water.
Six micro centrifuge tubes were filled with 1 ml of the
diluted solution and centrifuged for 3 minutes at
12,000 rpm. The supernatant was removed and dis-
carded, and the cells were suspended in an additional
1 ml of water, and then centrifuged again. This washing
process was repeated a total of three times. To make the
dye solution, 3 μL of dimethyl sulfoxide with 1.67 mM
SYTO 9 dye and 1.67 mM propidium iodide was sus-
pended in 1 ml water. Two hundred μL of this dye solu-
tion was added to the washed cells (currently suspended
in 1 ml water) to yield 1.2 ml of dyed cell solution.
Tubes were then stored in the dark at room tem-
perature for 30 minutes before use.
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Devices used in these experiments were a simple Y-channel
device with 3-in-1 units, with a 3 mm wide main channel,
1 mm tall inlet and outlet channels, and a channel height of
400 μm, providing a total channel volume of 60 μl. The
devices used for the final experiments were coated with
75 μg/ml rat-tail collagen, type I in 0.05 M hydrochloric
acid by filling through the outlet channel. After 2 h, the
device was aspirated, washed with sterile water, and left to
dry at room temperature for 1 h before use.
Bacterial flow and incubation
Five hundred μL of the dyed bacterial solution was
added to a glass syringe. The device was mounted onto a
microscope, and the syringe was connected via tubing
with Luer tapers. An outlet tube was connected to col-
lect any extra liquid. Using a syringe pump, bacteria
were flowed at a rate of 200 μl/h through the middle
channel for 1 h, while the top and bottom inlet reser-
voirs were sealed using Luer-compatible syringes or seals
(Figure 1A). Images were taken of the bacteria flow in
the outlet channel every minute during the bacterial flow
process. Tubing was disconnected and the device was
incubated for 4, 8, 12 or 24 hours at 35°C. Refer to
Figure 1B for an illustration of the operation of our
microfluidic device.
Efficacy testing of dispersin B and/or sterile water
After the device was incubated, 500 μl of sterile water was
added to a glass syringe and 500 μl of either DispersinB orFigure 1 Schematic diagram (A) of the microfluidic wound
model experimental setup. A Y-shaped microfluidic platform with a
microchannel served as a cell culture well mimicking an animal wound.
This 450 μm wide, 125 μm deep channel had a reservoir volume of
30 μL, and was connected on each side by two inlets and one outlet.
Single channel microfluidic device (B) formed from PDMS using soft
lithography techniques. For collagen-coated experiments, collagen was
flown through the inlet before testing the antimicrobials.sterile water was added to a second glass syringe. The de-
vice was mounted onto a microscope and the syringes
were connected via tubing with Luer tapers. An outlet
tube was connected with a micro-centrifuge tube to col-
lect the final solution for enumeration testing. Using a syr-
inge pump, DispersinB or sterile water was flowed at a
rate of 100 μL/h through the top channel, and sterile water
was flowed at a rate of 100 μl/h through the bottom chan-
nel for 4 hours, while the middle inlet reservoir was sealed
using a Luer-compatible syringe or seal (Figure 1B).
Images were taken every minute for the first 2 h at the
same location in the outlet channel that was used.
Enumeration testing
Micro centrifuge tubes were used to collect liquid sus-
pensions of cells from the outlet tube; serial dilutions of
these solutions were made to enumerate the collected
cells. We plated the 1:10, 1:100, and 1:1,000 dilutions
onto Columbia agar with 5% sheep blood. The plates
were incubated at 35°C for 24 h before the colonies were
counted.
Image analysis
Bacterial flow and post-incubation images were num-
bered in sequence prior to image analysis. Using
MATLAB Version R2013B (Mathworks Inc., Natick,
MA), images were read in order and Otsu thresholding
was performed to determine fluorescent intensity and
surface coverage. To numerically justify the results
from the image analysis readings, the area under the
curve formed in all surface coverage and intensity
graphs was measured and compared.
Micro-titre plate assay
Epidemiologically unrelated MRSP isolates from dogs
from different geographic regions were screened for bio-
film production via microtiter plate assay (MPA). Briefly,
overnight cultures were suspended in 5 ml of tryptic soy
broth (TSB) supplemented with 1% glucose to achieve
a turbidity equivalent to a 0.5 McFarland standard
(~108 CFU/ml). 200 μl of each inoculum was transferred
in triplicate to a 96-well polystyrene microtiter plate and
incubated under aerobic conditions for 24 h at 35°C.
Following incubation, the plates were washed three
times with phosphate buffered saline (PBS) to remove
non-adherent cells and then heat fixed at 60°C for 60
minutes. Adhered cells were dyed with 0.1% (w/v) of
crystal violet for 15 minutes and air dried at room
temperature. After resolubilization with 95% ethanol, op-
tical density (OD) reading of each well of the microtiter
plate was assessed, taken at 570 nm (OD570). Readings of
replicates for each isolate were averaged and subtracted
from the OD570 reading of the negative control. OD570
was used as indication of biofilm production. Isolates were
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further classified as strong, moderate, weak, or zero bio-
film formers based on their final OD570 reading.
Results and discussion
We monitored biofilm coverage inside the microfluidic
device after 4, 8, 12, and 24 h of biofilm growth. We began
monitoring at each of these time points and performed
constant monitoring (images taken every minute) over a
2 h period. When the percent surface area was calculated
and the readings were graphed, similar patterns in the
structure of the graphs were observed. We focused on the
results obtained from 12 and 24 h biofilms, as these time
points should yield mature structures consistent with
chronic wound infections. Surface coverage readings for
all four time points showed that 25-50% of the surface
was consistently covered with biofilm (Figure 2A, 2B, 2C
and 2D) and that relatively stable levels of coverage were
maintained over the 2 h imaging period.
The intensity of biofilm growth in regions across the
channel was parabolic as expected, since bacteria flowed
through the middle channel before incubation. Unexpect-
edly, when DispersinB-Gentamycin was used instead of
water in the top channel, it was found that the biofilm
intensity was greater on average. The average normalized
intensity value for 24 h biofilms was 0.536 for DispersinB-
Gentamycin and 0.500 for water alone, while at 12 h bio-
films it was found to be 0.599 for DispersinB-Gentamycin
and 0.411 for water alone. We propose that the apparent
increase in biomass may be a response to the stress in-
duced by treatment with antimicrobials. It is not uncom-
mon for the biofilm architecture to be altered in the
presence of inimical forces. For example, shear forces ap-
plied to biofilm have been shown to result in an increase
biofilm density [20].Figure 2 Biofilm coverage inside the microfluidic channels. This figure
after each of the denoted time points were reached, using water and Disp
and water, (B) 24 hours with water, (C) 12 hours with DispersinB and wateComparing the top half of the channel (Figure 3A)
with the bottom half of the channel (Figure 3B), we
noted that there was a great deal of contrast between
these images. All of our experiments produced data
with a bias towards the top half of the channel (more
biomass is located in this area), indicating that the de-
sign of the microfluidic device or the biofilm itself may
favour growth on that side of the device. After 24 h, the
top half of the channel held an average normalized value
of 0.747 when DispersinB-Gentamycin (Figure 3A) or
water alone (Figure 3B) was used, while the bottom half
held an average normalized value of 0.324 when Disper-
sinB was used and 0.253 when water alone (Figure 3B
and 3D) was used. After 12 h, the top half of the chan-
nel held an average normalized value of 0.765 when
DispersinB-Gentamycin was used (Figure 3C) and 0.499
when water was used, while the bottom half held an
average normalized value of 0.434 when DispersinB-
Gentamycin was used and 0.322 when water alone was
used. These results indicated that there was a greater
accumulation of biofilm in the top channel. Again, the ac-
cumulation (or lack of dispersion) was enhanced when the
biofilms were treated with DispersinB-Gentamycin, which
as suggested earlier may be due to a biofilm-promoting
response to treatment.
Microtitre plate assay readings confirmed previous re-
ports showing that DispersinB may be effective against
wound infection biofilms. We determined that there was an
inverse relationship between the DispersinB-Gentamycin
concentration and the level of biofilm growth in uncoated
wells (Figure 4A). There was also a relationship between
the effectiveness of DispersinB-Gentamycin and the biofilm
forming capabilities of the selected strain; better biofilm
forming strains showed a greater percent reduction in
the biomass following treatment. MRSP strain A12 wasdemonstrates the biofilm surface coverage during a period of 2 hours
ersinB treatments. Panels are as follows: (A) 24 hours with DispersinB
r and (D) 12 hours with water.
Figure 3 Biofilm fluorescence intensity inside the channels. This figure demonstrates the average fluorescence intensity (normalized) in the
channels during a period of 2 hours after the biofilms had reached the desired time point. Images are as follows: (A) 24 hours with DispersinB (B)
24 hours with water, (C) 12 hours with DispersinB, and (D) 12 hours with water.
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70.1%, and SP102 was only slightly reduced to 96.1% using
a 1:100 dilution of DispersinB-Gentamycin. This decline
was more prominent using1:1 dilutions of DispersinB-
Gentamycin; A12 was reduced to 11.9% of its control
value, A92 was reduced to 35.5%, and SP102 was reducedFigure 4 Microtitre plate assay findings. This figure demonstrates
the attachment of MRSP biofilm strains to (A) uncoated, and (B)
collagen-coated polystyrene surfaces after 24 h using various
concentrations of DispersinB-Gentamycin as noted. Crystal violet
was used to determine optical density.to 63.6%. For collagen-coated plates (Figure 4B), the re-
sults showed a weaker correlation. Taking any error into
account, each isolate showed a relatively stable level of
biofilm density when comparing control values to all the
concentrations of DispersinB-Gentamycin tested. The op-
tical density values were much lower in collagen-coated
tests (Figure 4B), with values routinely less than 0.5 com-
pared to values that ranged up to an optical density of
2.258 in uncoated tests. Rat tail collagen was used for
these studies, which is economical and readily available,
but we acknowledge that this may not be the ideal sub-
strate for MRSP attachment. In the future, we could test
more relevant sources of collagen to determine if this
improves overall biofilm formation.
Conclusions
Microfluidic tests performed as described in this study
showed that there was minimal biofilm shearing from
our microfluidic device, even following long periods of
idle incubation. Although, we determined that the ability
of DispersinB-Gentamycin to remove biofilm growth
was not dramatically different than treatment with water,
we contend that we have developed a successful model
to study chronic wound infections in animals. Uncoated
microtitre plate assays did confirm that DispersinB-
Gentamycin is capable of effectively removing biofilm
growth, which appears to be particularly effective against
strains that are strong biofilm formers. Additional stud-
ies with our microfluidic device may be necessary to de-
termine the best conditions for establishing a biofilm
that resembles those that form during wound infection.
We would suggest focusing on a strong biofilm forming
strain, such as A12, possibly incorporating smaller channel
widths or other sources or preparations of collagen.
Wound infections are typically polymicrobial [21]. Hence
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tions present in vivo. We also would consider incorporat-
ing host cells into our model, such as endothelial cells.
Ultimately, these results are preliminary, but we have de-
veloped a base model that may be modified to better emu-
late the conditions experienced in vivo during a chronic
wound infection. Our model is easy to use, space-saving,
and economical. Such a model may be highly effective in
mimicking a wound infection without resorting to invasive
testing of antimicrobial therapies in animals with wound
and surgical site infections.
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